Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | EIF4E | P06730 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2533703 | 0.89 | TSHR (0.55) | TSHRCES2CES1EIF4ENPC1 | |
| SCHEMBL17157028 | 0.87 | ALDH1A1 (0.52) | TSHRCES2CES1ALDH1A1MAPT | |
| SCHEMBL27585698 | 0.87 | CASP6 (0.51) | TSHRALDH1A1EIF4ESMN1; SMN2TDP1 | |
| SCHEMBL19025730 | 0.85 | ALDH1A1 (0.53) | TSHRALDH1A1EIF4EMAPTMYC | |
| SCHEMBL29789033 | 0.85 | ALDH1A1 (0.53) | TSHRALDH1A1EIF4EMAPTMYC | |
| SCHEMBL7053371 | 0.84 | MAPT (0.51) | TSHRALDH1A1EIF4EMAPTSMN1; SMN2 | |
| SCHEMBL8473662 | 0.83 | SLC25A1 (0.55) | ALDH1A1EIF4EMAPTMEN1LMNA | |
| SCHEMBL16538208 | 0.83 | EIF4E (0.51) | TSHRALDH1A1EIF4EMAPTSMN1; SMN2 | |
| SCHEMBL6261436 | 0.83 | SLC25A1 (0.55) | ALDH1A1EIF4EMAPTMEN1LMNA | |
| SCHEMBL12117513 | 0.82 | HSD17B10 (0.58) | TSHRCES2CES1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1181014-B1 | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2007-05-23 | — | — | EP | disclosed |
| US-6927227-B2 | Heterocyclic containing biphenyl aP2 inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-09 | — | — | US | disclosed |
| US-20030199563-A1 | Heterocyclic containing biphenyl aP2 inhibitors and method | ROBL JEFFREY A (US) | 2003-10-23 | — | — | US | disclosed |
| US-6548529-B1 | AP2 (adipocyte fatty binding protein); biphenyl-substituted pyrazoles of given formula; treating diabetes and related diseases; mixtures with other antidiabetic agents such as metformin, glyburide, troglitazone and/or insulin | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-15 | — | — | US | disclosed |
| EP-1181014-A4 | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2002-06-05 | — | — | EP | disclosed |
| CN-1345239-A | Heterocyclic containing biphenyl alpha P2 inhibitors and method | BRISTOL MYERS SQUIBB CO (US) | 2002-04-17 | — | — | CN | disclosed |
| EP-1181014-A1 | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000059506-A1 | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB CO. (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199563-A1 | Heterocyclic containing biphenyl aP2 inhibitors and method | AP2B1, AP2A2, AP2A1 | TSHR 734/4885CES2 2822/4885CES1 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.